Given the fact that cap-dependent translation regulated by the mTOR-4EBP1-eIF4E axis fine-tunes the expression of several oncoproteins, such as survivin, c-myc, cyclin D1, VEGF, and HIF-1α, all of which are called eIF4E-sensitive mRNAs, at the post-transcriptional level [18,19], therapeutic suppression of cap-dependent translation has been considered as a valuable strategy for cancer-targeted therapy. This evidence concerns the gene CCND1 and cancer.